Patents by Inventor Xiaozhao Wang

Xiaozhao Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KRAS INHIBITORS
    Publication number: 20260158024
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: November 12, 2025
    Publication date: June 11, 2026
    Inventors: Alexander Sokolsky, Rocco Policarpo, III, Xiaozhao Wang, Wenhao Zhang, Wenyu Zhu, Suman Chakrabarty, Chengtsung Lai, Haolin Yin, Nathaniel Greenwood
  • 6-6-FUSED BICYCLIC HETEROARYL AMINES AS CDK4 INHIBITORS
    Publication number: 20260132122
    Abstract: The present application provides compounds of Formula (I): or a pharmaceutically acceptable salt thereof, that are inhibitors of cyclin-dependent kinase 4 (CDK4), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: November 6, 2025
    Publication date: May 14, 2026
    Inventors: Liana Hie, Joshua Hummel, Xiaolei Li, Sharada Manns, Dibyendu Mondal, Shaoqun Qian, Xiaozhao Wang, Bo Wei, Ming Xiang
  • PYRIMIDINE INDOLES AS CDK4 INHIBITORS
    Publication number: 20260125391
    Abstract: The present application provides compounds of Formula (I): or a pharmaceutically acceptable salt thereof, that are inhibitors of cyclin-dependent kinase 4 (CDK4), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: November 4, 2025
    Publication date: May 7, 2026
    Inventors: Peter Niels Carlson, Liana Hie, Joshua Hummel, Jacob J. Lacharity, Xiaolei Li, Sharada Manns, Eli Ortiz, Robert Susick, Xiaozhao Wang, Bo Wei
  • Tetracyclic compounds as DGK inhibitors
    Patent number: 12600722
    Abstract: The present application provides tetracyclic compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: July 17, 2023
    Date of Patent: April 14, 2026
    Assignee: Incyte Corporation
    Inventors: Joshua Hummel, Shicheng Shi, Xiaozhao Wang
  • Tetracyclic compounds as DGK inhibitors
    Patent number: 12600723
    Abstract: The present application provides tetracyclic compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: July 17, 2023
    Date of Patent: April 14, 2026
    Assignee: Incyte Corporation
    Inventors: Joshua Hummel, Shicheng Shi, Xiaozhao Wang
  • Tricyclic compounds as inhibitors of KRAS
    Patent number: 12600717
    Abstract: Disclosed are compounds of Formula I (shown below), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: July 13, 2022
    Date of Patent: April 14, 2026
    Assignee: Incyte Corporation
    Inventors: Zhenwu Li, Zhiyong Yu, Jeremy Roach, Gia Hoang, Bin Hu, Gencheng Li, Rory McAtee, Ken Mukai, Rocco Policarpo, Robert Susick, Xiaozhao Wang, Wenqing Yao
  • FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS
    Publication number: 20260098041
    Abstract: The present application is concerned with tricyclic pyrimidinones as inhibitors of WRN, as well as pharmaceutical compositions and methods of use related thereto. The compounds are useful in treating, preventing, or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: February 26, 2025
    Publication date: April 9, 2026
    Applicant: Incyte Corporation
    Inventors: Le ZHAO, Yanran AI, Marc DELLER, Javier FELICIANO, Ananda GHOSH, Leslie McQUIRTER, Xiaozhao WANG, Eddy YUE, Guofeng ZHANG
  • SUBSTITUTED 7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINES AS SELECTIVE CDK2/4 INHIBITORS
    Publication number: 20260070915
    Abstract: The present application provides compounds of Formula (I): or a pharmaceutically acceptable salt thereof, that are inhibitors of cyclin-dependent kinase 2 and 4 (CDK2 and CDK4), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: September 11, 2025
    Publication date: March 12, 2026
    Inventors: Shicheng Shi, Joshua Hummel, Jacob J. Lacharity, Lei Liu, Eli Ortiz, Xiaozhao Wang, Bo Wei, Ming Xiang
  • KRAS INHIBITORS
    Publication number: 20260069605
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: September 11, 2025
    Publication date: March 12, 2026
    Inventors: Alexander Sokolsky, Yannick Boni, Gia Hoang, Bin Hu, Gencheng Li, Rocco Policarpo, III, Brandon Smith, Xiaozhao Wang, Michael Witten, Wenhao Zhang, Suman Chakrabarty
  • SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZIN-2-AMINES AS CDK2 AND CDK4 INHIBITORS
    Publication number: 20260070914
    Abstract: The present application provides compounds of Formula (I): or a pharmaceutically acceptable salt thereof, that are inhibitors of cyclin-dependent kinase 2 and 4 (CDK2 and CDK4), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: September 11, 2025
    Publication date: March 12, 2026
    Inventors: Yang Li, Joshua Hummel, Lei Liu, Shaoqun Qian, Xiaozhao Wang
  • PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS
    Publication number: 20260042765
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Application
    Filed: July 15, 2025
    Publication date: February 12, 2026
    Inventors: Yun-Long Li, Xiaozhao Wang, Joseph Barbosa, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Taisheng Huang, Song Mei, Jincong Zhuo
  • KRAS INHIBITORS
    Publication number: 20260034126
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: July 30, 2025
    Publication date: February 5, 2026
    Inventors: Alexander Sokolsky, Suman Chakrabarty, Bin Hu, Rocco Policarpo, III, Brandon R. Smith, Xiaozhao Wang, Michael R. Witten, Wenhao Zhang, Wenyu Zhu, Chunyin Marshall Law, Haolin Yin
  • Bicyclic DGK Inhibitors
    Publication number: 20260001880
    Abstract: The present application provides bicyclic compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: June 25, 2025
    Publication date: January 1, 2026
    Inventors: Joshua Hummel, Liana Hie, Jacob J. Lacharity, Xiaolei Li, Xiaozhao Wang, Bo Wei, Sarah Winterton
  • QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS
    Publication number: 20250368641
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: June 18, 2025
    Publication date: December 4, 2025
    Inventors: Qinda YE, Matthew MCCAMMANT, Rocco POLICARPO, Artem SHVARTSBART, Wenyu ZHU, Jeremy ROACH, Gia HOANG, Bin HU, Gencheng LI, Robert SUSICK, Padmaja POLAM, Fenglei ZHANG, Chao QI, Xiaozhao WANG, Wenqing YAO, Alexander Sokolsky, Haolin YIN, Le ZHAO, Peter Carlsen
  • BICYCLIC COMPOUNDS AS INHIBITORS OF WRN
    Publication number: 20250333419
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing, or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: August 30, 2024
    Publication date: October 30, 2025
    Applicant: Incyte Corporation
    Inventors: Joe Barbosa, Yanran Ai, Marc Deller, Balu D. Dherange, Ananda Ghosh, Joe Glenn, JR., Leslie McQuirter, Xiaozhao Wang, Eddy Yue, Guofeng Zhang
  • FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS
    Publication number: 20250333420
    Abstract: The present application is concerned with bicyclic pyrimidinones as inhibitors of WRN, as well as pharmaceutical compositions and methods of use related thereto. The compounds are useful in treating, preventing, or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: December 13, 2024
    Publication date: October 30, 2025
    Applicant: INCYTE CORPORATION
    Inventors: Stacey SHEPARD, Yanran AI, Joe BARBOSA, Marc DELLER, Ananda GHOSH, Joe Glenn, JR., Leslie McQUIRTER, Lixin SHAO, Xiaozhao WANG, Eddy YUE, Guofeng ZHANG
  • Naphthyridine compounds as inhibitors of KRAS
    Patent number: 12441742
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: August 30, 2022
    Date of Patent: October 14, 2025
    Assignee: Incyte Corporation
    Inventors: Gencheng Li, Haolin Yin, Chao Qi, Xiaozhao Wang, Wenqing Yao, Bin Hu, Peter Carlsen
  • Tricyclic compounds as inhibitors of KRAS
    Patent number: 12441727
    Abstract: Disclosed are compounds of Formula I, shown below, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: July 6, 2022
    Date of Patent: October 14, 2025
    Assignee: Incyte Corporation
    Inventors: Pei Gan, Jeffrey Yang, Yong Li, Le Zhao, Chunhong He, Chunyin Marshall Law, Xiaozhao Wang, Wenqing Yao
  • IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS
    Publication number: 20250313567
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: March 24, 2025
    Publication date: October 9, 2025
    Inventors: Xiaozhao Wang, Pei Gan, Heeoon Han, Taisheng Huang, Matthew S. McCammant, Chao Qi, Ding-Quan Qian, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Fenglei Zhang, Le Zhao, Chunhong He
  • Pyrrolotriazine compounds as tam inhibitors
    Patent number: 12415809
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Grant
    Filed: January 9, 2023
    Date of Patent: September 16, 2025
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Xiaozhao Wang, Joseph Barbosa, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Taisheng Huang, Song Mei, Jincong Zhuo